Advertisement

Topics

InterMune Pharmaceuticals Company Profile

01:48 EDT 20th September 2017 | BioPortfolio

InterMune, Inc., is a biopharmaceutical company focused on developing and commercializing innovative therapies in hepatology and pulmonology. We market Actimmune® (interferon gamma-1b), approved for the treatment of severe, malignant osteopetrosis and chronic granulomatous disease. We have a late-stage and preclinical development pipeline in the areas of pulmonology and hepatology. In pulmonology, we are developing two therapies for the treatment of idiopathic pulmonary fibrosis (IPF): interferon gamma-1b and pirfenidone. In hepatology, we are focused on expanding treatment options for patients suffering from HCV infections. We have identified and characterized several highly potent preclinical HCV protease inhibitor candidates and are rapidly progressing one of them through toxicology and other IND-enabling activities. In addition, we are pursuing research related to other small molecules for unspecified hepatology targets.

Location

3280 Bayshore Blvd.
Brisbane
CA
94005
United States of America

Contact

Phone: (415) 466-2200
Fax: (415) 466-2300
Email: ir@intermune.com


News Articles [1263 Associated News Articles listed on BioPortfolio]

InterMune to Present at J. P. Morgan Healthcare Conference

BRISBANE, Calif., Jan. 6, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the 32n...

InterMune To Present At JMP Securities Healthcare Conference

BRISBANE, Calif., July 2, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Dan Welch, Chairman, Chief Executive Officer and President of InterMune, will present at the JMP ...

InterMune to Release Second Quarter Financial Results on August 6

BRISBANE, Calif., July 28, 2014 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its second quarter 2014 financial results at the close of the U.S. markets on W...

InterMune To Release Fourth Quarter Financial Results On February 21

BRISBANE, Calif., Feb. 11, 2013 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its fourth quarter and full-year 2012 financial results at the close of the U.S. mar...

InterMune to Release Fourth Quarter and Full Year Financial Results on February 9

BRISBANE, Calif., Feb. 2, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its fourth quarter and full year 2011 financial results at the close of the U.S. mark...

InterMune Names Jonathan A. Leff, M.D., as Executive Vice President of Research and Development

BRISBANE, Calif., Feb. 9, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that Jonathan A. Leff, M.D., has been appointed InterMune's Executive Vice President of Resear...

InterMune Announces Proposed Concurrent Public Offerings Of Common Stock And Convertible Debt

BRISBANE, Calif., Jan. 14, 2013 /PRNewswire/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it plans to offer, subject to market and other conditions, $85.0 million aggregate principal amount ...

Deals this week: Pivot Pharmaceuticals, Innovation Pharmaceuticals, Portola Pharmaceuticals

Pivot Pharmaceuticals plans to acquire the worldwide rights to Altum Pharmaceuticals’ BiPhasix Transdermal drug delivery technology.

Drugs and Medications [271 Associated Drugs and Medications listed on BioPortfolio]

Actimmune [InterMune, Inc.]

ACTIMMUNE (Interferon gamma-1b)

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash

Bacitracin [Qualitest Pharmaceuticals]

Bacitracin Ointment, USP

Pur-wash [Niagara Pharmaceuticals Inc.]

Pur-Wash Purified Water, 98.3% Ophthalmic Solution Eyewash

Antacid [Major Pharmaceuticals]

Major Pharmaceuticals Antacid Tablets Drug Facts

PubMed Articles [157 Associated PubMed Articles listed on BioPortfolio]

Announcing the 2017 Pharmaceuticals Travel Award for Young Post-Doctoral Researchers.

Last year, for the first time in its history, our Journal was able to offer a travel grant of 800 CHF to a young researcher in the field of medicinal chemistry.

Suspended solids moderate the degradation and sorption of waste water-derived pharmaceuticals in estuarine waters.

This study focuses on the fate of pharmaceuticals discharged into an estuarine environment, particularly into the Turbidity Maximum Zone (TMZ). Batch experiments were set up to investigate the factors...

Chiral pharmaceuticals: A review on their environmental occurrence and fate processes.

More than 50% of pharmaceuticals in current use are chiral compounds. Enantiomers of the same pharmaceutical have identical physicochemical properties, but may exhibit differences in pharmacokinetics,...

Comparative study on pharmaceuticals adsorption in reclaimed water desalination concentrate using biochar: Impact of salts and organic matter.

The synergistic impact of salts and organic matter on adsorption of ibuprofen and sulfamethoxazole by three types of biochar and an activated carbon was investigated using reclaimed water reverse osmo...

Estimation of amount of selected pharmaceuticals sorbed onto digested sludge from wastewater treatment plant Bratislava-Petržalka.

Antibiotics and antidepressants are among the most successful drugs used for human therapy. Their concentration in influent on WWTP is relative high and there can be removed by biodegradation or sorpt...

Clinical Trials [199 Associated Clinical Trials listed on BioPortfolio]

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF

Open-label therapy will be administered to up to 220 patients, following completion of either InterMune Protocol GIPF-002 Part B or Protocol GIPF-004, to assess the long-term safety of sub...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects Under Fasting Condition

- Objective: - To compare the rate and extent of absorption of Citalopram Hydrobromide Tablets 40 mg: Test Product: Citalopram Hydrobromide Tablets 40 mg manufactured b...

Companies [1280 Associated Companies listed on BioPortfolio]

InterMune, Inc.

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopa...

InterMune Pharmaceuticals

InterMune, Inc., is a biopharmaceutical company focused on developing and commercializing innovative therapies in hepatology and pulmonology. We market Actimmune® (interferon gamma-1b), approved fo...

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Connetics Corporation

Connetics Corporation is focused on the acquisition, development and commercialization of marketed and late-stageproducts. The Company's product and commercial focus is initially targeted at rheumatol...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

More Information about "InterMune Pharmaceuticals" on BioPortfolio

We have published hundreds of InterMune Pharmaceuticals news stories on BioPortfolio along with dozens of InterMune Pharmaceuticals Clinical Trials and PubMed Articles about InterMune Pharmaceuticals for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of InterMune Pharmaceuticals Companies in our database. You can also find out about relevant InterMune Pharmaceuticals Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...


Corporate Database Quicklinks



Searches Linking to this Company Record